Search

Your search keyword '"Otsa, K."' showing total 76 results

Search Constraints

Start Over You searched for: Author "Otsa, K." Remove constraint Author: "Otsa, K."
76 results on '"Otsa, K."'

Search Results

1. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

2. Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study

3. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative

4. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative

6. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

7. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis

9. Update of EULAR recommendations for the treatment of systemic sclerosis

10. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative

11. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

12. European multicentre pilot survey to assess vitamin D and clinical status in rheumatoid arthritis patients

13. Update of EULAR recommendations for the treatment of systemic sclerosis

14. THU0116 European multicentre pilot survey to assess vitamin d and clinical status in rheumatoid arthritis patients

16. SAT0576 Associations between Five Important Domains of Health and The Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross Sectional Study of 977 Patients

17. Infliximab Plus Methotrexate Is Superior To Methotrexate Alone In The Treatment Of Psoriatic Arthritis In Methotrexate-Naive Patients: The Respond Study

18. Questra [SAT0515] country economy rather than disease activity predicts initiation of a biologic treatment over a 4-5 year follow up in a world-wide cohort of RA

20. Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe

22. SAT0398 Fatigue in Psoriatic Arthritis is Related to Disease Activity Rather than to Demographic Characteristics – an Ancillary Analysis of the Cross-Sectional International PSAID Study of 246 Patients

24. Rituximab (RTX) plus Methotrexate (MTX) prevents bone erosion and joint-space narrowing (JSN) and reduces synovitis, osteitis as shown on MRI: Results from a randomised, placebo-controlled trial in patients (PTS) with rheumatoid arthritis (RA-score).

25. OP0111 Elaboration and Preliminary Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire. A 13-Country Eular Initiative with Involvement of Patient Research Partners from Each Country

28. Rheumatoid Arthritis Impact of Disease Questionnaire

29. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative

32. The prevalence of rheumatoid arthritis in Estonia: an estimate based on rheumatology patients' database.

33. Gender, body mass index and rheumatoid arthritis disease activity: Results from the QUEST-RA study

34. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the european scleroderma trials and research (eustar) cohort

35. Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma Trials and Research cohort of patients with systemic sclerosis

36. A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study

37. Administrative database as a source for assessment of systemic lupus erythematosus prevalence: Estonian experience.

38. Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis.

39. Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study.

40. Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross-Sectional Study of 977 Patients.

41. European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new Patient Reported Outcome questionnaire (D-PRO).

42. Fatigue in psoriatic arthritis - a cross-sectional study of 246 patients from 13 countries.

43. Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study.

44. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.

45. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative.

47. Vitamin D in rheumatoid arthritis.

48. Vitamin D and rheumatoid arthritis: comment on the letter by Nielen et al.

49. Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe.

50. Circadian rhythms: glucocorticoids and arthritis.

Catalog

Books, media, physical & digital resources